Study guide
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health
Key Takeaways Explain This Topic AI
Basson's circular model describes responsive desire, in which arousal from context and intimacy can precede desire, a common normal pattern in long-term relationships.
DSM-5-TR female sexual dysfunctions (sexual interest/arousal disorder, orgasmic disorder, and genito-pelvic pain/penetration disorder) require symptoms for at least 6 months with clinically significant distress.
Flibanserin (nightly) and bremelanotide (on demand by injection) are FDA-approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lesbian and bisexual women need the same cervical cancer screening as heterosexual women because HPV spreads through skin-to-skin and digital contact.
Transgender women who use estrogen remain at risk for prostate cancer, and breast screening generally begins at 40 after at least 5 years of hormone therapy.
Last updated: October 2026
Models of Sexual Response
Masters and Johnson (linear): Excitement, plateau, orgasm, resolution.
Kaplan (triphasic): Desire, arousal, orgasm.
Basson (circular): Many women, especially in long-term relationships, begin from sexual neutrality; willingness and emotional intimacy lead to arousal, and responsive desire follows arousal. Satisfaction depends on emotional and physical outcomes, not only orgasm. Lack of spontaneous desire alone is not a disorder.
Taking an Inclusive Sexual History
Ask every patient, using gender-neutral language: "Are your partners men, women, both, or people of other genders?" Record sexual orientation and gender identity (SOGI) separately, because orientation does not predict behavior.
Use the CDC 5 Ps (partners, practices, protection from STIs, past STIs, pregnancy intention) and ask about satisfaction, pain, and concerns.
PLISSIT model for sexual concerns:
P ermission: invite discussion and normalize concerns.
L imited I nformation: education about anatomy, aging, and medication effects.
S pecific S uggestions: lubricants, positions, sensate focus, scheduling.
I ntensive T herapy: referral to sex therapy, pelvic floor physical therapy, or specialists.
DSM-5-TR Female Sexual Dysfunctions
All require symptoms for at least 6 months that cause clinically significant distress and are not better explained by another disorder, relationship distress, or a medication.
Disorder Core Features Common Contributors
Female sexual interest/arousal disorder Absent or reduced interest, thoughts, initiation, excitement, or genital sensation Depression, SSRIs, relationship conflict, fatigue, low estrogen
Female orgasmic disorder Delayed, infrequent, or absent orgasm, or reduced intensity SSRIs and SNRIs, inadequate stimulation, anxiety
Genito-pelvic pain/penetration disorder Pain with penetration, fear of pain, pelvic floor tightening Vulvodynia, GSM, vaginismus, endometriosis, trauma history
The International Society for the Study of Women's Sexual Health still uses hypoactive sexual desire disorder (HSDD) , the term in FDA labeling.
Assessment
Review medications (SSRIs, SNRIs, antipsychotics, antiandrogens, opioids, and sometimes hormonal contraception), mood, relationship, trauma history, chronic illness, and menopausal status. Examine for GSM, vulvar dermatoses, vestibular tenderness (cotton-swab test), pelvic floor hypertonicity, and pelvic masses.
Treatment
Sex therapy, couples therapy, CBT, and mindfulness have the strongest evidence for desire and arousal concerns.
Medication-induced dysfunction: Lower the dose, switch to bupropion , or add bupropion.
Dyspareunia from GSM: Lubricants and moisturizers, then low-dose vaginal estrogen, vaginal DHEA (prasterone), or oral ospemifene.
Genito-pelvic pain: Pelvic floor physical therapy and graduated vaginal dilators; treat any underlying condition.
Vulvodynia (vulvar pain for at least 3 months without an identifiable cause; provoked vestibulodynia is most common): Remove irritants, use topical lidocaine before intercourse, consider tricyclic antidepressants or gabapentinoids, and refer to pelvic floor physical therapy.
Drug for HSDD Use Key Safety Points
Flibanserin (Addyi) 100 mg nightly at bedtime; premenopausal women with acquired, generalized HSDD Hypotension and syncope; wait at least 2 hours after 1–2 drinks before the dose, or skip it; avoid with moderate or strong CYP3A4 inhibitors; stop if no benefit after 8 weeks
Bremelanotide (Vyleesi) 1.75 mg subcutaneous injection at least 45 minutes before sexual activity; no more than 1 dose per 24 hours or 8 per month Nausea, transient blood pressure rise, focal hyperpigmentation; avoid with uncontrolled hypertension or cardiovascular disease
Testosterone (off-label) Transdermal therapy for postmenopausal HSDD (Global Consensus, 2019) No FDA-approved female product in the United States; keep levels in the premenopausal range and monitor for androgenic effects
- Sexual and Reproductive Health for LGBTQ+ Patients
- Lesbian, Bisexual, and Queer Women
Cervical cancer screening follows the same schedule as for any person with a cervix; HPV spreads through skin-to-skin and digital contact, and many have had male partners.
STI risk is real: BV is common and often concordant between female partners, and trichomoniasis, HSV, and HPV can be transmitted. Test according to reported practices.
Ask about contraception rather than assuming it is not needed.
Higher rates of tobacco and alcohol use, obesity, depression, and anxiety, partly from minority stress , call for proactive screening.
Family building: donor insemination, reciprocal IVF, and the legal steps that protect both parents.
Transgender and Gender-Diverse Patients
Screen by organ inventory , not by gender marker.
Transgender men and nonbinary people with a cervix: Cervical screening continues; testosterone is not contraception (see the health equity section).
Transgender women: Prostate tissue remains, so prostate cancer remains possible (PSA runs lower on estrogen). Breast screening is generally recommended from age 40 after 5 or more years of feminizing hormones (American College of Radiology). Estrogen therapy raises VTE risk, especially with smoking.
Use the patient's name and pronouns and affirming anatomic terms, and make sure intake forms, restrooms, and records are inclusive.
Sexual Health Across the Life Course
Pregnancy and postpartum: Intercourse is safe in an uncomplicated pregnancy. After birth, resume when bleeding has slowed and the patient feels ready; lactation lowers estrogen and causes dryness, so recommend lubricants and, if needed, low-dose vaginal estrogen. Address fatigue, body image, and contraception.
Menopause: Genitourinary syndrome of menopause causes dryness and dyspareunia that worsen without treatment, while desire changes often reflect relationship, mood, and health factors as much as hormones.
Chronic illness and cancer: Diabetes, multiple sclerosis, pelvic surgery, radiation, and endocrine therapy for breast cancer often affect sexual function. Ask directly, because many patients will not raise the topic first.